Rising CEA With Normal Scans: — Where Does PET Actually Help?

There is no single level that automatically triggers a PET scan. Your oncologist is watching for a pattern — a confirmed rising trend across consecutive tests — rather than any single number. The trajectory matters more than the value at one point. A sustained increase above your post-treatment baseline, particularly when CT has not found an explanation, is what prompts further investigation. Ask your team specifically what trend they are tracking in your case, because the threshold depends on your history and your baseline after treatment ended.

A negative PET with a rising CEA is genuinely uncertain territory. It does not mean there is no recurrence — it means PET has not detected one at this point. Small deposits, mucinous histology, peritoneal spread, and low-grade tumours can all raise CEA without appearing on PET. Your team will usually monitor more closely, repeat imaging at a shorter interval, or consider MRI of specific sites if a location is suspected. Ask what the plan is if PET is negative, before you have the scan.

PET is less reliable for peritoneal disease than for deposits in solid organs. Small implants on the peritoneal surface often fall below PET resolution, and peritoneal disease does not always show high glucose uptake. CT and MRI — reviewed by a radiologist with specific experience in peritoneal disease — add information that PET misses in this location. If peritoneal recurrence is a concern based on your original staging or current symptoms, raise it directly so your team can plan the right combination of investigations.

Your team will not stop at a single negative scan. Next steps usually include repeating imaging at a shorter interval, using MRI to examine specific sites in greater detail, or — if peritoneal disease is suspected — a diagnostic laparoscopy. CEA that rises persistently without an imaging explanation is managed with close surveillance, not reassurance, until the source is found or the trajectory changes. Ask your oncologist what the specific plan is after a negative PET so you know what comes next and when.

No. NCCN and ASCO do not recommend PET as a substitute for CT in standard post-treatment surveillance. CT remains the baseline imaging for most follow-up visits. PET earns its place in a targeted situation: when CEA rises and CT is negative, or when CT shows a change that needs further characterisation. Routine PET at every follow-up visit adds cost and radiation without improving outcomes for most patients — the evidence supports it in specific, problem-solving scenarios, not blanket surveillance.

PET is less reliable in mucinous adenocarcinoma than in standard colorectal cancer, and your team should factor in your histology before interpreting the result. Mucinous tumours tend to produce lower glucose uptake, which means a negative PET is less reassuring than it would be for a standard tumour. It does not mean PET has no role — it can still detect some recurrences — but a negative result in a mucinous tumour with a rising CEA requires further investigation, not a clear bill of health. Ask your oncologist explicitly how your original histology affects how they read this scan.